FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (Rapid PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
fj.06-7439comv1
21/4/1145    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsche, G.
Right arrow Articles by Malle, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsche, G.
Right arrow Articles by Malle, E.
Published online before print January 11, 2007 as doi: 10.1096/fj.06-7439com.

Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway

Gunther Marsche, Michaela Semlitsch, Astrid Hammer, Sasa Frank, Bernd Weigle, Nina Demling, Kurt Schmidt, Werner Windischhofer, Georg Waeg, Wolfgang Sattler, and Ernst Malle

E-mail contact: ernst.malle@meduni-graz.at

Signal transduction via the endothelial receptor for advanced glycation end products (RAGE) plays a key role in vascular inflammation. Recent observations have shown that the myeloperoxidase-H2O2-chloride system of activated phagocytes is highly up-regulated under inflammatory conditions where hypochlorous acid (HOCl) is formed as the major oxidant. Albumin, an in vivo carrier for myeloperoxidase is highly vulnerable to oxidation and a major representative of circulating advanced oxidized proteins during inflammatory diseases. Immunohistochemical studies performed in the present study revealed marked colocalization of HOCl-modified epitopes with RAGE and albumin in sections of human atheroma, mainly at the endothelial lining. We show that albumin modified with physiologically relevant concentrations of HOCl, added as reagent or generated by the myeloperoxidase-H2O2-chloride system, is a high affinity ligand for RAGE. Albumin, modified by HOCl in the absence of free amino acids/carbohydrates/lipids to exclude formation of AGE-like structures, induced a rapid, RAGE-dependent activation of extracellular signal-regulated kinase 1/2 and up-regulation of the proinflammatory mediator monocyte chemoattractant protein-1. Cellular activation could be blocked either by a specific polyclonal anti-RAGE IgG and/or a specific mitogen-activated protein-kinase kinase inhibitor. The present study demonstrates that HOCl-modified albumin acts as a ligand for RAGE and promotes RAGE-mediated inflammatory complications.--Marsche, G., Semlitsch, M., Hammer, A., Frank, S., Weigle, B., Demling, N., Schmidt, K., Windischhofer, W., Waeg, G., Sattler, W., Malle, E. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. Marsche, P. G. Furtmuller, C. Obinger, W. Sattler, and E. Malle
Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro
Cardiovasc Res, July 1, 2008; 79(1): 187 - 194.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
R. RAMASAMY, S. F. YAN, K. HEROLD, R. CLYNES, and A. M. SCHMIDT
Receptor for Advanced Glycation End Products: Fundamental Roles in the Inflammatory Response: Winding the Way to the Pathogenesis of Endothelial Dysfunction and Atherosclerosis
Ann. N.Y. Acad. Sci., April 1, 2008; 1126(1): 7 - 13.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. Marsche, B. Weigle, W. Sattler, and E. Malle
Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein
FASEB J, October 1, 2007; 21(12): 3075 - 3082.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. Herold, B. Moser, Y. Chen, S. Zeng, S. F. Yan, R. Ramasamy, J. Emond, R. Clynes, and A. M. Schmidt
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress
J. Leukoc. Biol., August 1, 2007; 82(2): 204 - 212.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by The Federation of American Societies for Experimental Biology.